medigraphic.com
ISSN 2007-6053 (Impreso)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2011, Número 2

<< Anterior Siguiente >>

Evid Med Invest Salud 2011; 4 (2)


Quimioterapia neoadyuvante en cáncer de mama

Hernández-Hernández CA, Reyes-Contreras JG, Kuri-Exsome R, Matadamas-Zarate C, Valencia-Mijares NM

Idioma: Español
Referencias bibliográficas: 44
Paginas: 54-64
Archivo PDF: 263.29 Kb.


RESUMEN

El cáncer de mama es la principal neoplasia maligna a nivel mundial. México, no es la excepción y desde el año 2006 éste se ubica como la primera causa de muerte en mujeres menores de 50 años; en ese año fallecieron 4,451 mexicanas (un fallecimiento cada dos horas). De los pacientes de reciente diag- nóstico, 50% de los casos se encuentran en estadios III y IV de cáncer de mama, requiriendo de tratamientos más largos, complejos, costosos y menos efectivos. Los objetivos del tratamiento con la quimioterapia neoadyuvante son incrementar las cirugías conservadoras de la mama, determinar la respuesta al tratamiento neoadyuvante in vivo y aumentar la supervivencia libre de enfermedad. Los principales estudios comparativos con quimioterapia neoadyuvante utilizan antraciclinas y taxanos ya sea en forma concomitante o secuencial. La respuesta patológica completa es el principal predictor de supervivencia. Los pacientes con Her2 positivo son considerados para recibir quimioterapia neoadyuvante más trastuzumab. Sin embargo, existen pocos estudios comparativos en cáncer de mama localmente avanzado y/o inflamatorio, lo que crea un área de oportunidad para investigación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.- Julio Frenk. Editorial. Sensibilización, detección temprana y combate a los prejuicios. Claves en la lucha contra el cáncer de mama. Salud Pública de México 2009;51; 51(2):suplemento: suplemento S135-S137.

  2. 2.- Lozano R., Knaul F.M., Gómez Dantés H., et al. Tendencias en la mortalidad por cáncer de mama en México, 1979– 2006. Observatorio de la Salud. Documento de trabajo. Competitividad y Salud, Fundación Mexicana para la Salud; 2008.

  3. 3.- Felicia Marie Knaul, Gustavo Nigenda, Rafael Lozano, Hector Arreola- Ornelas, Ana Langer, Julio Frenk. Breast cancer in Mexico: a pressing priority. Reproductive Health Matters 2008;16; 16(32):113–123.

  4. 4.- Jacobo Alejandro Gómez-Rico. Marina Altagracia-Martínez. Jaime Kravzov-Jinich. Rosario Cárdenas-Elizalde. Consuelo Rubio-Poo. The costs of breast cancer in a Mexican public health institution. Risk Management and Healthcare Policy 2008:1 15–21.

  5. 5.- J. Mathew. K.S. Asgeirsson a, K.L. Cheung a, S. Chan b, A. Dahda b, J.F.R. Robertson. Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions. Eur J Surg Oncol 2009;35:113; 35:113-122.

  6. 6.- Sharon H. Giordano. Update on Locally Advanced Breast Cancer. Oncologist 2003;8:521; 8:521-530.

  7. 7.- M anfred Kaufmann, Gunter von Minckwitz, Roy Smith, Vicente Valero, et al. International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendati ons. J Clin Oncol 2003;21:2600; 21:2600-2608.

  8. 8.- Manfred Kaufmann, Gabriel N. Hortobagyi, Aron Goldhirsch, Suzy Scholl, et al. Recommendati ons From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update. J Clin Oncol 2006;24:1940; 24:1940-1949.

  9. 9.- Stephen Chia, Sandra M. Swain, David R. Byrd, and David A. Mankoff. Locally Advanced and Inflammatory Breast Cancer. J Clin Oncol 2008;26:786; 26:786-790.

  10. 10.- Davide Mauri, Nicholas Pavlidis , John P. A. Ioannidis. Neoadjuvant Versus Adjuvant Adjuvant Systemic treatment in Breast Cancer: A Meta-Analysis. J Natl Cancer Inst 2005;97:188; 97:188–94)

  11. 11.- Shen J., Valero V., Buchh olz T.A., et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004;11:854; 11:854-860.

  12. 12.- Jos A. van der Hage, Cornelis J.H. van de Velde, Jean-Pierre Julien, Michelle Tubiana-Hulin, Cecile Vandervelden, Luc Duchateau. Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224; 19:4224-4237.

  13. 13.- Fisher B., Bryant J., Wolmark N., Mamounas E., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672; 16:2672- 2685.

  14. 14.- Priya Rastogi, Stewart J. Anderson, Harry D. Bear, Charles E. Geyer, et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778; 26:778-785.

  15. 15.- Günther G. Steger, Arik Galid, Michael Gnant, Brigitte Mlineritsch, et al. Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony- Stimulating Factor in Operable Breast Cancer: Results of ABCSG-

  16. J Clin Oncol 2007;25:2012; 25:2012-2018.

  17. 16.- Minckwitz G., Kümmel S., Vogel P, Hanusch C., et al. Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomi zed GeparTrio Study. J Natl Cancer Inst 2008;100; 100: 552 – 562.

  18. 17.- Minckwitz G., Kümmel S., Vogel P., Hanusch C., et al. Neoadjuvant Vinorelbine – Capecitabine Versus Docetaxel – Doxorubicin – Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomi zed GeparTrio Trial. J Natl Cancer Inst 2008;100:542; 100:542-551.

  19. 18.- Marjorie C. Green, Aman U. Buzdar, Terry Smi th, Nuhad K. Ibrahi m, et al. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. J Clin Oncol 2005;23:5983; 23:5983-5992

  20. 19.- C . Mazouni, S.-W. Kau, D. Frye, F. Andre, et al. Inclusion of taxanes, particularly weekly paclitaxel in preoperative chemotherapy improves pathologic complete response rate in estrogen receptorpositive breast cancers. Annals of Oncology 2007;18:874; 18:874–880.

  21. 20.- Bear H., Anderson S., Brown A., Smi th R., et al. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results Fromfrom National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-4174.

  22. 21.- Priya Rastogi, Stewart J. Anderson, Harry D. Bear, Charles E. Geyer, et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778; 26:778-785.

  23. 22.- Smith I.C., Heys S.D., Hutcheo A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456; 20:1456-1466.

  24. 23.- Alvarez R.H., Bianchi ni G., Hsu L., et al. Clinical outcome of two sequences of administering paclitaxel (P) and anthracyclines (A) as primary systemic therapy (PST) and adjuvant chemotherapy (ACT ) in breast cancer (BC) patients; a retrospective analysis from the M.D. Anderson Cancer Center (MDACC ). San Antonio Breast Cancer Symposium 2010. Abst. P5-10-02.

  25. 24.- Minckwitz G., Costa S., Raab G., Blohmer J., et al. Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony- Stimulating Factor Support With with or Without Tamoxifen as Preoperative Therapy in Patients Withwith Operable Carcinoma of the Breast: A Randomi zed, Controlled, Open Phase IIb Study. J Clin Oncol 2001;19:3506; 19:3506-3515.

  26. 25.- P. Therasse, L. Mauriac, M. Welnicka- Jaskiewicz, P. Bruning, et al. Final Results of a Randomi zed Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose- Intensified Epirubicin and Cyclophosphami de _ Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC -NCIC-SAKK Multicenter Study. J Clin Oncol 2003; 21:843-850.

  27. 26.- Georgiana K. Ellis, William E. Barlow, Julie R. Gralow, Gabriel N. Hortobagyi, et al. Phase III Comparison of Standard Doxorubicin and Cyclophosphami de Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012. J ¬_Clin Oncol 2011;28:1; 28:1-8.

  28. 27.- Julie R. Gralow, Harold J. Burstein, William Wood, Gabriel N. Hortobagyi, et al. Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. J Clin Oncol 2008;26:814; 26:814-819.

  29. 28.- Keith N. Ogston, Iain D. Miller, Simon Payne, Andrew W. Hutcheon, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. The Breast 2003;12:320; 12:320–327.

  30. 29.- Fang Fan. Evaluation and Reporting of Breast Cancer after Neoadjuvant Chemotherapy. The Open Pathology Journal 2009;3:58; 3:58-63.

  31. 30.- De Laurentii s M., Cancello G., D’Agostino D., et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomi zed trials. J Clin Oncol 2008;26:44; 26:44-53.

  32. 31.- Bria E., Nistico C., Cuppone F., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer : Pooled analysis of 15,500 patients. Cancer 2006;106:2337; 106:2337-2344.

  33. 32- Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663; 358:1663- 1671.

  34. 33.- Dahabreh I.J., Linardou H., Siannis F., Fountzilas G., Murria S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systemic review and meta-analysis of randomi zed controlled trials. Oncologist 2008;13:620; 13:620-630.

  35. 34.- Buzdar A.U., Ibrahi m N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676; 23:3676-3685.

  36. 35.- Gianni L., Ei ermann W., Semi glazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast cancer (the NOA H trial): a randomised controlled superiorita trial with a parallel HER2-negative cohort. Lancet 2010;375:377; 375:377-384.

  37. 36.- Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024; 28:2024- 2031.

  38. 37.- Von Minckwitz G., Rezai M., Loibl S., et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients wi th primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010;28:2015; 28:2015-2023.

  39. 38.- Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomi zed trials. Anti-Cancer Drugs 2011;22:128; 22:128-135.

  40. 39.- Baselga J., Bradbury I., Ei dtmann H., et al, on the behalf of the NeoALTTO Study Team. San Antonio Breast Cancer Symposium 2010. Abstr. S3-3.

  41. 40.- Gianni L., Pienkowski T., Im Y-.H., et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomi zed phase III study (‘NeoSphere’). San Antonio Breast Cancer Symposium 2010. Abstr. S3-2.

  42. 41.- Suparna Bonthala Wedam, Jennifer A. Low, Sherry X. Yang, Catherine K. Chow, et al. Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer. J Clin Oncol 2006;24:769; 24:769-777.

  43. 42.- Alessandra Balduzzi, Emilia Montagna, Vincenzo Bagnardi, Rosalba Torrisi, et al. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anti-Cancer Drugs 2009, 20:197–203.

  44. 43.- R. Greil, M. Moik, R. Reitsamer, S. Ressler, et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. Eur J Surg Oncol 2009;35:1048; 35:1048-54.




2020     |     www.medigraphic.com